Alimta ® (pemetrexed for injection)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Alimta Summary of Product Characteristics (SmPC)

Alimta® (pemetrexed): Vitamin Supplementation

Prior to pemetrexed treatment, initiate vitamin supplementation consisting of oral folic acid and IM vitamin B12 to reduce severity of pemetrexed toxicity.

Detailed Information

To reduce toxicity, patients treated with pemetrexed must be instructed to take a folic acid preparation or a multivitamin with folic acid

  • as a daily oral low-dose

  • initiated during the 7-day period preceding the first dose of pemetrexed, and for at least 5 doses, and

  • during the full course of therapy and for 21 days after the last dose of pemetrexed.

In clinical trials, the dose of folic acid studied ranged from 350 to 1000 mcg. The most commonly used dose of oral folic acid in clinical trials was 400 mcg.

Patients must also receive vitamin B12

  • as an IM injection

  • initiated the week preceding the first dose of pemetrexed, and

  • every 3 cycles thereafter.

Subsequent vitamin B12 injections may be given the same day as pemetrexed. In clinical trials, the dose of vitamin B12 received was 1000 mcg.

Effects of Vitamin Supplementation on Toxicity

In the phase 3 MPM registration trial, pretreatment with folic acid and vitamin B12 led to overall less toxicity and reduction in grade 3/4 hematologic and nonhematologic toxicities such as

  • neutropenia

  • febrile neutropenia, and

  • infection with grade 3/4 neutropenia.

Therefore, patients treated with pemetrexed must be instructed to take folic acid and vitamin B12 as a prophylactic measure to reduce treatment-related toxicity.

Effects of Vitamin Supplementation on Pharmacokinetics

The PK of pemetrexed are not influenced by oral folic acid and IM vitamin B12 supplementation.

Glossary

IM = intramuscular

MPM = malignant pleural mesothelioma

PK = pharmacokinetic(s)

Date of Last Review: October 15, 2018

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question